Odronextamab: "Follicular Lymphoma: Potential best-in-class efficacy"; Follicular lymphoma and diffuse large B- cell lymphoma (Regeneron Pharmaceuticals) - Dec 14, 2023 - ASH 2023: "DLBCL: Consistent and competitive efficacy profile"
P2 data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Oncology
|